Press release
Persistent Epithelial Defect (PEDs) Market to Reach USD 2.5 Billion by 2034
Persistent epithelial defects (PEDs) are corneal lesions where the corneal epithelium fails to heal within two weeks despite standard therapy. They arise from multiple causes, including ocular trauma, corneal infections, neurotrophic keratitis, dry eye disease, post-surgical complications, and autoimmune conditions. PEDs can lead to scarring, secondary infections, corneal perforation, and vision loss, making effective management essential.Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72273
The global market is driven by rising cases of ocular surface diseases, post-surgical complications (e.g., LASIK, cataract), and neurotrophic keratitis. Significant advances in regenerative medicine, biologics, and ocular surface therapies such as amniotic membrane transplantation and recombinant growth factors are redefining treatment approaches.
Market Overview
• Market Size (2024): USD 1.2 billion
• Forecast (2034): USD 2.5 billion
• CAGR (2025-2034): 7.7%
Key Highlights:
• Increasing prevalence of dry eye disease, diabetes-related ocular complications, and corneal trauma.
• Expansion of amniotic membrane and biologic-based ocular surface therapies.
• R&D in regenerative approaches (nerve growth factors, stem cells, recombinant proteins).
• Rising demand for novel drug delivery systems and biologic eye drops.
Segmentation Analysis
By Treatment Type:
• Conventional Therapy
o Artificial Tears & Lubricants
o Bandage Contact Lenses
o Punctal Plugs
• Advanced Therapy
o Amniotic Membrane Transplantation
o Recombinant Growth Factors (e.g., cenegermin - nerve growth factor)
o Stem Cell Therapy
o Biologic Eye Drops (serum-based, autologous preparations)
• Surgical Interventions (tarsorrhaphy, keratoplasty)
By Cause/Indication:
• Neurotrophic Keratitis (major share)
• Dry Eye Disease & Ocular Surface Disorders
• Corneal Trauma & Post-Surgical PEDs
• Infectious Corneal Ulcers
• Autoimmune-Related PEDs
By End Use:
• Hospitals & Specialty Eye Clinics
• Ambulatory Surgical Centers
• Academic & Research Institutes
• Retail & Online Pharmacies (supportive products)
Segmentation Summary:
Traditional lubricants and contact lenses provide short-term relief, while advanced biologics, recombinant growth factors, and regenerative therapies are the fastest-growing treatment segment.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72273/persistent-epithelial-defect-peds-market
Regional Analysis
North America
• Largest market (~42% share in 2024).
• High prevalence of ocular surface disorders and strong adoption of biologics.
• FDA approval of cenegermin (Oxervate) boosting growth.
Europe
• ~31% share.
• Germany, UK, and France lead adoption of amniotic membrane and biologic therapies.
• EMA support for rare ocular surface disorders such as neurotrophic keratitis.
Asia-Pacific
• Fastest-growing region, CAGR ~8.6%.
• Large patient pool with high incidence of ocular trauma, infections, and diabetes-related PEDs.
• Expanding corneal transplantation and regenerative therapy programs in Japan, China, and India.
Latin America
• Brazil and Mexico gradually expanding access to biologic therapies.
Middle East & Africa
• GCC countries strengthening ophthalmology infrastructure.
• Limited availability of advanced biologics in most African nations.
Regional Summary:
North America and Europe dominate the market, but Asia-Pacific is set to grow fastest due to its large patient base and increasing adoption of regenerative therapies.
Market Dynamics
Key Growth Drivers:
• Rising global incidence of corneal trauma, ocular surface disorders, and post-surgical complications.
• Expanding adoption of biologics like cenegermin and amniotic membrane therapies.
• Advances in stem cell therapy and ocular regenerative medicine.
• Growing investments in ophthalmic R&D and biologic drug delivery systems.
Key Challenges:
• High cost of biologics and regenerative therapies.
• Limited availability of amniotic membrane and stem cell therapy in low-income regions.
• Recurrence of PEDs in high-risk patients.
• Variability in treatment response across causes.
Latest Trends:
• Cenegermin (Oxervate) setting a benchmark in biologic eye therapy.
• Growth of stem cell-derived corneal epithelial cell therapies.
• Development of nanoparticle-based drug delivery for ocular surface repair.
• Integration of AI-powered ocular surface imaging for early detection and monitoring.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72273
Competitor Analysis
Major Players in the Market:
• Dompé Farmaceutici S.p.A. (Oxervate - cenegermin)
• Novartis AG
• Johnson & Johnson Vision Care
• Alcon Inc.
• Bausch + Lomb
• Santen Pharmaceutical Co., Ltd.
• Ocular Therapeutix, Inc.
• Regeneron Pharmaceuticals, Inc.
• Allergan (AbbVie Inc.)
• Stem cell and biotech start-ups in ocular regenerative research
Competitive Summary:
Dompé leads with Oxervate, the first FDA- and EMA-approved biologic for neurotrophic keratitis-related PEDs. Alcon, J&J Vision, and Bausch dominate surgical and supportive care. Biotech companies and academic labs are driving breakthroughs in stem cell and regenerative therapies, setting the stage for long-term innovation.
Conclusion
The Persistent Epithelial Defect (PEDs) Market, valued at USD 1.2 billion in 2024, is projected to reach USD 2.5 billion by 2034, growing at a CAGR of 7.7%.
Key Takeaways:
• Neurotrophic keratitis is the leading cause of PEDs.
• Conventional treatments are being replaced by biologics and regenerative approaches.
• North America and Europe lead in adoption, while Asia-Pacific shows the fastest growth.
• Stem cell therapies, biologics, and AI diagnostics represent the future of PEDs management.
The next decade will bring a shift from supportive care to disease-modifying regenerative therapies, offering patients improved vision outcomes and reduced risk of corneal blindness.
This report is also available in the following languages : Japanese (持続性上皮欠損(PED)市場), Korean (지속성 상피 결손(PED) 시장), Chinese (持续性上皮缺损(PED)市场), French (Marché des défauts épithéliaux persistants (DEP)), German (Markt für persistente Epitheldefekte (PEDs)), and Italian (Mercato dei difetti epiteliali persistenti (PED)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72273/persistent-epithelial-defect-peds-market#request-a-sample
Our More Reports:
Mitochondrial Epilepsy Market
https://exactitudeconsultancy.com/reports/72869/mitochondrial-epilepsy-market
TIL Therapy Market
https://exactitudeconsultancy.com/reports/72870/til-therapy-market
Peptide Therapeutics Market
https://exactitudeconsultancy.com/reports/72871/peptide-therapeutics-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent Epithelial Defect (PEDs) Market to Reach USD 2.5 Billion by 2034 here
News-ID: 4194199 • Views: …
More Releases from Exactitude Consultancy

Oral Oncolytics for Leukemia Market to Reach USD 12.98 Billion by 2034, Growing …
Introduction
The global fight against leukemia-a complex group of hematological malignancies-has entered a revolutionary new phase. The development of oral oncolytics has shifted cancer care away from hospital-based infusions toward more convenient, targeted, and patient-friendly therapies. These drugs empower patients to receive continuous, effective treatment from the comfort of their homes while maintaining better quality of life and adherence.
According to Exactitude Consultancy, the global Oral Oncolytics for Leukemia Market was valued…

DNA Synthesis Market to Reach USD 9.58 Billion by 2034, Growing at a CAGR of 11. …
Introduction
The growing convergence of biotechnology, data science, and automation is transforming how humanity designs and manipulates life's fundamental code-DNA. The DNA synthesis market lies at the heart of this revolution, enabling researchers to create custom genetic sequences for applications ranging from drug discovery and personalized medicine to agriculture, industrial enzymes, and genetic engineering.
According to Exactitude Consultancy, the global DNA Synthesis Market was valued at USD 3.25 billion in 2024 and…

DNA and Gene Cloning Services Market Projected to Reach USD 5.96 Billion by 2034
Introduction
In the era of genetic medicine and biotechnology, DNA and gene cloning services play an indispensable role in advancing research, diagnostics, and therapeutic innovation. By enabling the precise replication and manipulation of genes, cloning technologies are empowering scientists to design custom DNA sequences, engineer novel biomolecules, and develop next-generation drugs and vaccines.
According to Exactitude Consultancy, the global DNA and Gene Cloning Services Market was valued at USD 2.15 billion in…

Next-Generation Antibody Therapeutics Market Projected to Reach USD 18.9 Billion …
Introduction
Antibody therapeutics have long been the cornerstone of targeted medicine, but the next generation of antibody technologies is transforming the landscape of immunotherapy and biologic drug development. From bispecific antibodies and antibody-drug conjugates (ADCs) to Fc-engineered and antibody fragments, next-generation antibody therapeutics (NGATs) represent a paradigm shift toward higher precision, potency, and reduced toxicity.
According to Exactitude Consultancy, the global Next-Generation Antibody Therapeutics Market was valued at USD 6.8 billion in…
More Releases for PED
Persistent Epithelial Defect Market Projected to Grow at 7.4% CAGR, Reaching USD …
Introduction
Persistent epithelial defects (PEDs) are corneal wounds that fail to heal within the expected timeframe despite conventional treatment. These defects are caused by various underlying conditions such as neurotrophic keratopathy, severe dry eye, trauma, chemical burns, or post-surgical complications. If left untreated, PEDs can progress to corneal ulcers, scarring, and even permanent vision loss, making them a serious ophthalmic concern.
The complexity of PED treatment lies in addressing not only the…
Ped-Lock Valves & Fittings
• Company Overview
Established in 1985, Ped Lock is ISO 9001:2015-certified and manufactures a wide range of instrumentation valves, fittings, and hydraulic components.
• Product Portfolio
Includes needle, ball, check, gate, globe, safety/relief, manifold, condensate pot, quick release valves, air headers, hydraulic hose, and more.
• Certifications & Quality Assurance
Equipped with advanced machining, in-house R&D and labs, and rigorous testing (leakage, hydro, helium, seismic, etc.).
• Global Presence
Products are exported worldwide, including to the USA, UK, Germany, Australia, and…
Persistent Epithelial Defect Market Size is Set for Rapid Growth as Innovative T …
The Persistent Epithelial Defect market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Dompe Farmaceutici, Amber Ophthalmics, Kala Bio, Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Amber Ophthalmics, Inc., Noveome Biotherapeutics, formerly Stemnion, Amber Ophthalmics, Inc.
[Nevada, United States] - DelveInsight's "Persistent Epithelial Defect Market Insights, Epidemiology, and Market Forecast 2034." report offers a…
Foot Care Medicated Creams Market Upcoming Trends, Segmented by Type, Applicatio …
New Jersey, United States,- Mr Accuracy Reports published new research on Global Foot Care Medicated Creams covering micro level of analysis by competitors and key business segments (2022-2029). The Global Foot Care Medicated Creams explores comprehensive study on various segments like opportunities, size, development, innovation, sales and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists both qualitative and quantitative…
Pipeline Embolization Device (PED) Market Emerging Trends, Growth Factors, Regio …
Los Angeles-United State: QY Research has recently published a research report titled, "Global Pipeline Embolization Device (PED) Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application" assessing various factors impacting its trajectory. The global Pipeline Embolization Device (PED) market report offers a high-quality, accurate, and comprehensive research study to equip players with valuable insights for making strategic business choices. The research analysts have provided…
Strongly Increasing Market of Gas Scooter Market Report 2019-2025: Top Key Playe …
UpMarketResearch offers a latest published report on “Global Gas Scooter Market Analysis and Forecast 2018-2025” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 113 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Get Exclusive FREE Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/49493
Gas Scooter Market research report delivers a close…